Sarah Ringwald

Award winning oncology specialist focused on the leukemia, lymphoma and multiple myeloma market in the North Texas and East Texas markets for the last 10 years.

Expertly navigated academic and community oncology practices to identify appropriate patients for Imbruvica and Darzalex.

In an intensely competitive market, maintained a constant competitive mindset to keep patients on Imbruvica in an environment with intense pathway and payer pressures.

With key relationships within Texas Oncology, worked with the local market team to advance positioning, advocacy and patient first focus to become a leading industry partner with Texas Oncology.

Created and led a One Janssen team within the Dallas VA that was comprised of cross functional members from the J&J enterprise, including members from Immunology, Cardiology, Infectious Disease, Neuroscience and Oncology.